Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphona

Byeong Bae Park, Baek Yeol Ryoo, Jae H. Lee, Hyuck C. Kwon, Sung H. Yang, Hye J. Kang, Hyo J. Kim, Sung Y. Oh, Young H. Ko, Joo R. Huh, Seung S. Lee, Eun M. Nam, Keon W. Park, Jung H. Kim, Jung H. Kang, Soo M. Bang, Sarah Park, Kihyun Kim, Keunchil Park, Cheolwon SuhWon S. Kim

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The objective of this retrospective study was to investigate clinical features and treatment outcomes in patients with angioimmunoblastic T-cell lymphoma (AITL), data of which were collected over a 15-year period. Sixty-five patients diagnosed with AITL were included in the study. About half of the patients (46.2%) presented with poor performance status (ECOG ≥2); 72.3% of patients belonged to high intermediate or high-risk of IPI and same proportion belonged to Class 2 of PIT (Prognostic index for PTCL-U), and most patients (95.4%) were diagnosed at an advanced stage. At diagnosis, 27 patients (41.5%) presented with malignant pleural effusion, and 22 patients (33.8%) had skin involvement. Most of the initial chemotherapy regimens were anthracycline-based (88.2%). Overall response rate to initial chemotherapy was 86.2% (64.7% of complete response, 21.5% of partial response). The median progression-free survival and overall survival of all patients was 7.1 months (95% CI, 2.8-11.4) and 15.1 months (95% CI, 6.7-23.5), respectively. Age, performance status, and PIT scores were predictive prognostic factors for survival. In conclusion, although AITLs showed a good response to the initial chemotherapy, their response durations were short; therefore, chemotherapy for AITL should be modified or intensified as in high-dose chemotherapy.

Original languageEnglish
Pages (from-to)716-722
Number of pages7
JournalLeukemia and Lymphoma
Issue number4
StatePublished - Apr 2007


  • Angioimmunoblastic T-cell lymphoma
  • Clinical features
  • Treatment outcomes


Dive into the research topics of 'Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphona'. Together they form a unique fingerprint.

Cite this